





Laskar, P., Somani, S., Campbell, S. J., Mullin, M., Keating, P., Tate, R. J., Irving, C., 
Leung, H. Y. and Dufès, C. (2019) Camptothecin-based dendrimersomes for gene 
delivery and redox-responsive drug delivery to cancer cells. Nanoscale, 11(42), pp. 
20058-20071. 
 
   
There may be differences between this version and the published version. You are 




http://eprints.gla.ac.uk/201505/                



































Camptothecin-based dendrimersomes for gene delivery and redox-responsive 
drug delivery to cancer cells 
Partha Laskar†, Sukrut Somani†, Sara Jane Campbell†, Margaret Mullin&, Patricia Keating‡, 
Rothwelle J. Tate†, Craig Irving‡, Hing Y. Leung§, Christine Dufès† * 
 
† Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 
Cathedral Street, Glasgow G4 0RE, United Kingdom 
& College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, 
United Kingdom 
‡ Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, 
Glasgow G1 1XL, United Kingdom  
§ Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, 
Glasgow, G61 1BD, United Kingdom 
 
Corresponding Author 
* Corresponding author: Christine Dufès 
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 
Cathedral Street, Glasgow G4 0RE, United Kingdom 
Phone: 44 -141 548 3796 















Combination therapy involving chemotherapeutic drugs and genes is emerging as a promising 
strategy to provide a synergistic therapeutic effect, to overcome drug resistance while reducing 
the severe side effects associated with conventional chemotherapeutic drugs. However, the lack 
of nanomedicines able to simultaneously carry anti-cancer drugs and nucleic acids limits the 
application of this therapeutic strategy.  To overcome this issue, we proposed to synthesize a pro-
drug dendrimer by conjugating the PEGylated, positively charged generation 3-diaminobutyric 
polypropylenimine dendrimer to the anti-cancer drug camptothecin with a redox-sensitive 
disulphide linkage, and evaluate its efficacy to co-deliver the complexed DNA and camptothecin 
to cancer cells. This PEGylated pro-drug dendrimer was found to spontaneously self-assemble 
into cationic (~3-5 mV) vesicles at pH 7.4, at a critical aggregation concentration of about 200 
µg/mL. These vesicles (dendrimersomes) became smaller (150-200 nm) with increasing 
dendrimer concentration and remained stable over 7 days. They were able to release about 70% 
of the conjugated camptothecin in presence of 50 mM glutathione (equivalent to the intracellular 
environment of tumor tissue). They could also condense more than 85% of the DNA at 
dendrimer: DNA weight ratios of 5:1 and higher. DNA condensation occurred instantly and was 
found to be stable for at least 24 h. This led to an enhanced cellular uptake of DNA (by up to 1.6-
fold) and increased gene transfection (by up to 2.4-fold) in prostate cancer cells in comparison 
with the unmodified dendrimer. These novel dendrimersomes are therefore promising for single 

















The combination of chemotherapy and gene therapy within nanomedicines has the 
potential to provide a synergistic therapeutic effect, to overcome drug resistance while limiting 
the severe side effects generally associated with traditional anti-cancer drugs.1-3 However, the 
lack of delivery systems able to simultaneously carry anti-cancer drugs and nucleic acids and to 
selectively deliver them to cancer tissues without secondary effects still limits the application of 
this therapeutic strategy.2-4 To overcome this issue, we propose to synthesize a pro-drug 
dendrimer by conjugating the PEGylated, positively charged generation 3-diaminobutyric 
polypropylenimine (DAB) dendrimer to the anti-cancer drug camptothecin (CPT) with a redox-
sensitive disulphide linkage, and evaluate its efficacy to co-deliver the complexed DNA along 
with CPT to cancer cells. 
Cationic dendrimers have recently been reported as promising non-viral carriers for 
nucleic acid and drug delivery to cancer cells.5-7 These three-dimensional macromolecules 
present the advantages of being highly branched, with modifiable surface functionalities leading 
to the successful conjugation of targeting moieties and the binding of drugs or nucleic acids for 
therapeutic applications.5-7 Due to their positive charge, cationic dendrimers not only can form 
stable dendriplexes with negatively charged genetic materials, but can also easily bind to the 
negatively charged cell surface followed by cellular internalization via endocytosis through 
electrostatic interactions. 5-7 Furthermore, their high aqueous solubility, low toxicity and compact 
globular shapes, with internal cavities delimited by constitutive dendrons make these dendrimers 
ideal carriers for therapeutic agents, facilitating the passive targeting of anticancer drugs to tumor 
tissues due to the enhanced permeability and retention (EPR) effect.8 In this work, generation 3-
diaminobutyric polypropylenimine (DAB) dendrimer was selected due to its higher gene 
transfection efficacy compared with the other generations of polypropylenimine dendrimers. The 
tumor-targeted generation-3 DAB dendrimer complexed to therapeutic plasmid DNA on mice 
models has previously led to tumor regression and even tumor suppression on various cancer cell 
types.9-12 In addition, polyethylene glycol (PEG) is a well-known stealth material to enhance 
circulatory lifetime of any drug and gene delivery systems by increasing their water solubility 
and reducing non-specific interactions with circulatory proteins.13-16 Recently, we observed that 
the conjugation of low-molecular-weight PEG (2 kDa) to generation 3- and generation 4-DAB 
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dendrimers significantly reduced their cytotoxicity, thereby increasing gene expression in 
various cells lines compared to unmodified dendrimers.17  Therefore, we have chosen a 
heterobifunctional PEG of MW 2 kDa, orthopyridyl disulfide (OPSS) polyethylene glycol 
(PEG2000) succinimidyl carboxymethyl ester (OPSS-PEG-SCM), to be conjugated on the 
surface of DAB dendrimer surface through amide bond to make this delivery system stealthy. 
Camptothecin (CPT), a naturally occurring alkaloid, is a potent chemotherapeutic agent 
with promising preclinical anti-cancer efficacy.18-19 Structure–activity studies have shown that 
the closed lactone ring and the C-20-OH group of this highly hydrophobic drug are responsible 
for cell damage by binding to DNA topoisomerase I through the lactone ring.18-19 Its use as anti-
cancer drug is currently limited by its poor aqueous solubility, inactivation of its lactone ring at 
physiological pH, severe toxicity and rapid blood clearance. 18-19 To overcome this, the 
conjugation of CPT using its 20-OH group to a water-soluble nanocarrier was found not only to 
increase its aqueous solubility, but also to stabilize its lactone ring at physiological pH.20-23 The 
preparation of such water-soluble polymer-CPT conjugate by converting CPT into an inactive 
but more stable prodrug able to revert back to the pharmacologically active agent following 
biological stimuli, resulted in improved drug pharmacokinetics and increased the accumulation 
of CPT in tumors by the enhanced permeation and retention (EPR) effect.20-24 Furthermore, the 
conjugation of the hydrophobic CPT to any water-soluble polymer led to the formation of  varied 
nanostructures based on hydrophobic-hydrophilic balance.25-28  
Various self-assembled nanostructures, such as micelles or vesicles,  resulting from the 
conjugation of diverse hydrophobic groups to the surface of dendritic molecules have recently 
been reported for biomedical applications.29-33 Based on this, we planned in this study to  
synthesize an amphiphilic macromolecule by conjugating a hydrophobic CPT to a hydrophilic 
PEGylated DAB dendrimer through disulphide linkage (-S-S-), with the hope that it would self-
assemble in water due to hydrophobic interactions within the conjugated CPT molecules. The 
presence of a disulphide linkage in its backbone should make it sensitive to the reducing biothiol 
glutathione (GSH), , resulting in the destruction of the delivery systems followed by the release 
of the drug at the desired site of action.34-36 The occurrence of GSH was found to be different in 
intracellular (∼10 mM) and extracellular (<10 μM) compartments of living cells, and nearly 4-
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fold higher in cancer cells than in normal tissues, making it a particularly  interesting stimulus 
for cancer therapy.34-36 
In this study, our objectives were therefore (1) to synthesize and characterize CPT-
anchored PEGylated DAB dendrimer through redox-sensitive disulphide (-S-S-) linkage, (2) to 
evaluate its self-assembly formation into nanostructures, (3) to assess its redox-responsiveness, 
(4) to study its DNA condensation ability (5) to assess its cell viability, cellular uptake and 








Generation 3-diaminobutyric polypropylenimine (DAB) dendrimer was purchased from SyMO-
Chem (Eindhoven, The Netherlands). Orthopyridyl disulfide (OPSS) polyethylene glycol 
(PEG2000) succinimidyl carboxymethyl ester (OPSS-PEG-SCM) was from JenKem Technology 
(Plano, TX). Camptothecin (CPT), glutathione (GSH), 3-tritylsulfanylpropionic acid, 4-
dimethylaminopyridine (DMAP) and N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC), Nile Red (NR), Coumarin 153 (C153), Biodialyser (double sided, sample 
reservoir size 1000 μL), anhydrous dichloromethane (DCM), triethylsilane (TESi), 
trifluoroacetic acid, diethyl ether, 2,5-dihydroxybenzoic acid (DHB), deuterated solvents 
DMSO-d6, CDCl3 and D2O, were obtained from Sigma Aldrich (Poole, UK). HPLC grade 
acetonitrile and methanol came from Fisher Scientific (Loughborough, UK). The expression 
plasmid encoding β-galactosidase (pCMVsport β-galactosidase) was from Invitrogen (Paisley, 
UK) and purified using an Endotoxin-free Giga Plasmid Kit (Qiagen, Hilden, Germany). MilliQ 
water (with a resistivity of 18.2 MΩ.cm at 25 oC) was collected using a Milli-Q® Integral water 
purification system from Merck (Kenilworth, NJ). Tissue culture media and Quanti-iT® 
PicoGreen® dsDNA reagent was purchased from Life Technologies (Paisley, UK). Vectashield® 
mounting medium containing propidium iodide (PI) came from Vector Laboratories 
(Peterborough, UK). Label IT® Fluorescein and Cy5 Nucleic Acid Labeling Kit were obtained 
from Cambridge Biosciences (Cambridge, UK). Bioware® androgen-irresponsive PC-3M-luc- C6 
human prostate adenocarcinoma cell line able to express the firefly luciferase was purchased 
from Caliper Life Sciences (Hopkinton, MA). 
 
2.2. Synthesis of thiolated camptothecin (CPT-SH) 
Thiolated camptothecin (CPT-SH) was synthesized following a method reported by Zhou and 
colleagues.37 Briefly, CPT (40 mg, 0.1148 mmol), 3-tritylsulfanylpropionic acid (40.01 mg, 
0.1148 mmol), DMAP (24.21 mg, 0.1263 mmol) and EDC (15.43 mg, 0.1263 mmol) were mixed 
in anhydrous DCM (4 mL). The reaction mixture was stirred overnight at 20 oC and then filtered 
using Whatman cellulose filter paper (Diameter: 18.5 cm, Pore Size: 11 µm).  The solvent was 
evaporated from the filtrate and the residue was re-dissolved in 4 mL of anhydrous DCM, 
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followed by the sequential addition of triethylsilane (0.5 mL) and trifluoroacetic acid (0.8 mL). 
The reaction mixture was then stirred for 2 h at 20 oC before removal of DCM and TFA by 
evaporation for 2 h. The residual reaction mixture was redissolved in 500 µL DCM and then 
poured into an excess of cold diethyl ether (15 mL) to precipitate the final product, a yellow 
powder which was collected and dried under vacuum in the hood (yield of 88%).  1H-NMR 
spectra of CPT-SH (1 mg in 0.5 mL DMSO-d6) was recorded using a Bruker Avance® III-
HD500 NMR spectrometer (Billerica, MA), based on residual proton resonance of the solvent as 
the internal standard (Figure S1). 
 
2.3. Synthesis of disulphide-linked camptothecin-bearing PEGylated dendrimer (DAB-
PEG-SS-CPT or DPSSC) 
Amine-terminated, generation 3-diaminobutyric polypropyleneimine (DAB) dendrimer was first 
conjugated to PEG using OPSS-PEG-SCM and then to thiolated camptothecin through 
disulphide linkage using DMSO as solvent (Figure 1) through in situ two-step reaction. Briefly, 
DAB (1 equivalent, 60 mg) was solubilized in 1.5 mL DMSO for 10 minutes at 20 oC. A freshly 
prepared solution of OPSS-PEG-SCM (1 equivalent, 81.59 mg) in 1.5 mL DMSO was added 
dropwise to DAB over 10-12 minutes. The light yellow colored reaction mixture was then stirred 
at 37 oC for 6 h, protected from light. Thiolated camptothecin (2 equivalents, 31.03 mg in 1.5 mL 
DMSO) was then added as a whole to the reaction mixture containing PEGylated DAB. The 
resulting solution, initially light yellow, gradually became darker and was left stirring at 37 oC, 
protected from light. After 16 h, the red-brown colored reaction mixture was dialyzed against 
DMSO (500 mL) for 2 days, then against methanol (500 mL) for 2 days and finally dialyzed 
against distilled water (2 L) for 2 days at 20 oC, using a dialysis tubing with a molecular weight 
cut-off of 3.5 kDa to remove the unreacted thiolated CPT, excess PEG and organic solvents 
respectively. The dialysis medium was changed twice per day. The dialyzed solution was then 
filtrated with Whatman cellulose filter paper (diameter: 18.5 cm, pore size: 11 µm) and freeze-
dried using a Christ Epsilon 2-4 LSC freeze dryer (Osterode am Harz, Germany). The final 
product DAB-PEG-SS-CPT or DPSSC, a red colored compound (yield of 59%), was stored at 0-
4 oC for long-term storage. 1H-NMR spectrum of DPSSC (3.12 mg in 0.5 mL CDCl3) was 
8 
 
recorded using Bruker Avance® III-HD500 NMR spectrometer (Billerica, MA) based on residual 
proton resonance of the solvent as the internal standard. 
 
2.4. Reverse-phase high performance liquid chromatography (RP-HPLC) 
Phenomenex-Gemini C18 RP-HPLC column (150 x 4.60 mm) was used for reverse-phase HPLC 
to determine the purity of DPSSC. Milli-Q water containing 0.05% trifluoroacetic acid (Eluant 
A) and acetonitrile containing 0.05% trifluoroacetic acid (Eluant B) were used as solvents to 
elute the sample. The mobile phase for isocratic elution was run with 25% Eluant A and 75% 
Eluant B at a flow rate of 1 mL/min for 10 min. The volume of each injection was 10 µL, and the 
detection of the eluted DPSSC sample was performed at 360 nm.  
 
2.5. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-
TOF MS) 
2,5-dihydroxybenzoic acid was used as a matrix to determine the molecular weight of DPSSC 
and its starting materials DAB and OPSS-PEG-SCM using MALDI-TOF mass spectrometry 
(Axima CFR, Kratos, Shimadzu, Kyoto, Japan). The sample (10 µL in ultrapure water) was 
added to the matrix solution (10 µL, 10 mg/mL in methanol) in 1:1 (v:v) ratio and mixed. The 
mixture solution (1 µL) was placed on a MALDI sample plate. All the spots were dried before 
measurement and the instrument was first calibrated with four standards and operated in a linear 
mode with a N2 laser operating at 337 nm to generate the ions, which were then accelerated to 20 
kV. Mass spectra of DPSSC and its starting materials mainly exhibited singly charged molecular 
ions [M]+ with their fragmented products.  
 
2.6. Fluorescence spectra of DPSSC and CPT in DMSO 
Fluorescence spectra of DPSSC and CPT solutions in DMSO were recorded with a Varian Cary 
Eclipse Fluorescence spectrophotometer (Palo Alto, CA) (λexc: 365 nm, λem: 375-700 nm, 





2.7. Entrapment of Nile Red within DPSSC 
The ability of DPSSC to self-assemble was evaluated by steady-state fluorescence technique 
using hydrophobic fluorescence probe Nile Red. Nile Red stock solution (16 µL, 3.14 × 10−3 M, 
0.98 mg in 0.98 mL methanol) was added to 5-mL plastic vials. Following complete evaporation 
of the methanol after 5-6 h, 1 mL DPSSC dendrimer solutions prepared at concentrations ranging 
from 0.05 to 3500 µg/mL in PBS (pH 7.4), was added to the vials, making the final probe 
concentration 50 µM. Each sample was vigorously vortexed for 5 minutes and then incubated for 
24 h at 25 oC, protected from light. Nile Red fluorescence spectrum was recorded for each 
sample with a Varian Cary Eclipse Fluorescence spectrophotometer (Palo Alto, CA) (λexc: 600 
nm, λem: 620-800 nm, excitation and emission slits at 10 nm and 20 nm respectively). 
 
2.8. Fluorescence spectra of DPSSC in phosphate buffer (pH 7.4) 
Fluorescence spectra of DPSSC at different concentrations (0.2, 0.5. 1.0 and 2.0 mg/mL) in 
phosphate buffer (pH 7.4) were recorded with a Varian Cary Eclipse Fluorescence 
spectrophotometer (Palo Alto, CA) (λexc: 365 nm, λem: 375-700 nm, excitation and emission slits 
at 5 nm). All the solutions were incubated for 24 h before fluorescence measurement.  
 
2.9. Transmission electron microscope (TEM) 
The morphology of DPSSC-based nanostructures at various concentrations (200, 1000 and 2000 
µg/mL in PBS pH 7.4) was determined using a JEOL JEM-1200EX transmission electron 
microscope (Jeol, Tokyo, Japan) operating at an accelerating voltage of 80 kV. After a minimum 
24-h incubation, sample solution (3 µL) was drop-cast on a carbon-coated copper grid (400 mesh 
size), dried in a desiccator overnight, before imaging. 
 
2.10. Hydrodynamic size and zeta potential of self-assembling DPSSC  
Dynamic light scattering (DLS) was used to measure the hydrodynamic diameter (dH) and the 
zeta potential of DPSSC (200 to 2000 µg/mL) in PBS (pH 7.4) at 37 oC, with a Malvern NanoZS 
(Malvern Instruments, Malvern, UK). He-Ne laser (λ = 632.8 nm, 4 mW) was used as a source 
and scattering photons were collected at 173o scattering angle. 
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The stability of DPSSC in presence of foetal bovine serum (FBS) was also assessed by 
measuring the size of DPSSC (2000 µg/mL) in complete medium containing 10% (FBS) at 
various time intervals.  
 
2.11. Micropolarity of DPSSC self-aggregates 
Micropolarity of DPSSC self-aggregates was measured using a hydrophobic fluorescent probe, 
coumarin-153 (C153). A stock solution of C153 (1.0 × 10−3 M, 3.19 mg in 10 mL methanol) was 
prepared and 2 µL of this solution was added to 5-mL plastic vials. Following complete 
evaporation of the methanol after 5-6 h, 1 mL DPSSC prepared at various concentrations (0, 0.2, 
0.5, 1 and 2 mg/mL in PBS pH 7.4) was added to the vials, making the final probe concentration 
2 × 10−6 M. Each sample solution was vigorously vortexed for 5 minutes and then incubated for 
24 h at 25 oC, protected from light, before measurement. The fluorescence emission spectrum of 
C153 probe in aqueous phosphate buffer (pH 7.4), was recorded in the presence of DPSSC at 
various concentrations (λexc: 420 nm, λem: 430-700 nm, excitation and emission slits at 5 nm and 
10 nm respectively), using a Varian Cary Eclipse Fluorescence spectrophotometer (Palo Alto, 
CA). The frequency of C153 fluorescence emission was used to calculate the micropolarity of 
the microenvironment of the aggregates, which is expressed by π*-polarity scale, as follows: 
 
ῡem = 21.217 ‒ 3.505π∗ 
 
where, ῡem [in 103 cm−1] is the wavenumber corresponding to the emission maximum of C153. 
  
2.12. Circular Dichroism (CD) spectroscopy 
Chirascan V100 (Applied Photophysics, Leatherhead, Surrey, UK) with a 150W air-cooled 
Xenon arc lamp was used to record CD spectra (190-700 nm), using a 10 mm path length quartz 
UV- Vis absorption cell (Hellma Analytics, Müllheim, Germany). Dendrimer solutions (2 
mg/mL in DMSO and phosphate buffer pH 7.4) were prepared and incubated overnight before 
measurement at 25 oC. Background spectra of the different solvents (DMSO and phosphate 




2.13. Redox-sensitive CPT release  
The redox-triggered release of CPT from DPSSC was assessed using glutathione, a biological 
reducing agent. DPSSC (5 mg/mL) and glutathione solutions (100 mM and 100 µM) were 
prepared in phosphate buffer (pH 7.4). Samples of DPSSC (1 mg/mL) in presence or absence of 
various glutathione concentrations (0, 10 µM, 10 mM and 50 mM) were prepared as follows:  
(i) No GSH: 200 μL of DPSSC (5 mg/mL) with 800 μL buffer (pH 7.4) 
(ii) 10 μM GSH: 200 μL of DPSSC (5 mg/mL) with 700 μL buffer (pH 7.4) and 100 μL 
glutathione solution (100 μM) 
(iii) 10 mM GSH: 200 μL of DPSSC (5 mg/mL) with 700 μL buffer (pH 7.4) and 100 μL 
glutathione solution (100 mM) 
(iv) 50 mM GSH: 200 μL of DPSSC (5 mg/mL) with 300 μL buffer (pH 7.4) and 500 μL 
glutathione solution (100 mM).  
 
 Two sides of the biodialyser were closed using 3500 MWCO dialysis bag. Each 
biodialyser containing DPSSC with various GSH concentrations (0, 10 µM, 10 mM and 50 mM) 
was then immersed in 60 mL of phosphate buffer (pH 7.4) having the same GSH concentration 
as inside the biodialyser. The samples were then incubated in the dark under stirring condition 
(100 rpm) at 37 oC for 7 days. Release of the CPT was measured by taking out 1 mL aliquot 
from the release media and replacing with 1 mL of fresh media at different time intervals. Each 
measurement was repeated in triplicates. An absorbance based calibration curve of CPT in 
phosphate buffer (pH 7.4) was prepared to calculate the concentration of released CPT from 
DPSSC at different time intervals. 
 
2.14. Redox-sensitive change of size and zeta potential of DPSSC dendrimersomes  
The hydrodynamic diameter and zeta potential of DPSSC in phosphate buffer (pH 7.4) incubated 
with glutathione were measured at various time intervals over 7 days at 37 oC by dynamic light 
scattering (DLS), using a Malvern Nano ZS instrument (He-Ne laser, λ = 632.8 nm, 4 mW, 173o 
scattering angle, Malvern Instruments, Malvern, UK) (Figures S10 and Table S2). Samples of 
DPSSC (1.2 mL, 1 mg/mL) in presence or absence of various glutathione concentrations (0, 10 
µM, 10 mM and 50 mM) were prepared as follows:  
12 
 
(i) No GSH: 240 μL of DPSSC (5 mg/mL) with 960 μL buffer (pH 7.4) 
(ii) 10 μM GSH: 240 μL of DPSSC (5 mg/mL) with 840 μL buffer (pH 7.4) and 120 μL GSH 
solution (100 μM) 
(iii) 10 mM GSH: 240 μL of DPSSC (5 mg/mL) with 840 μL buffer (pH 7.4) and 120 μL GSH 
solution (100 mM) 
(iv) 50 mM GSH: 240 μL of DPSSC (5 mg/mL) with 360 μL buffer (pH 7.4) and 600 μL GSH 
solution (100 mM)  
 
2.15. Evaluation of DNA condensation  
2.15.1. PicoGreen assay 
PicoGreen® assay was performed according to the supplier's protocol to assess the ability of 
DPSSC to complex the negatively charged plasmid DNA encoding β-galactosidase at various 
dendrimer: DNA weight ratios (20:1, 10:1, 5:1, 2:1, 1:1, 0.5:1 and 0:1) in Tris–EDTA (TE) 
buffer (10 mM Tris, 1 mM EDTA, pH 7.5). DNA solution (500 μL, 10 μg/mL in TE buffer) was 
added to each dendrimer solution (500 μL in TE buffer) and vortexed to prepare 1 mL complex 
at various weight ratios. PicoGreen® reagent was then diluted (200-fold in TE buffer) on the day 
of the experiment, and one mL PicoGreen® solution was added to the TE buffer with or without 
complexes and vortexed immediately before the first measurement. The fluorescence emission 
intensity of PicoGreen® (λexc: 480 nm, λem: 520 nm, excitation and emission slits: 5 nm each) in 
presence of the DPSSC complexes was measured at various time intervals using a Varian Cary 
Eclipse Fluorescence spectrophotometer (Palo Alto, CA). Results were represented as percentage 
of DNA condensation. 
Fluorescence emission spectra of PicoGreen® (λexc: 480 nm, λem: 490-700 nm, excitation and 
emission slits: 5 and 5 nm) and DPSSC (λexc: 365 nm, λem: 375-700 nm, excitation and emission 
slits: 5 and 10 nm) were recorded using a Varian Cary Eclipse Fluorescence spectrophotometer 
(Palo Alto, CA). 
Fluorescence spectra of PicoGreen and DPSSC showed no change in emission maximum in 
dendriplexes in comparison to their native spectra, confirming that there was no physical 




2.15.2. Gel retardation assay 
DNA condensation ability of DPSSC was also tested using a gel retardation assay at dendrimer: 
DNA weight ratios 20:1, 10:1, 5:1, 2:1, 1:1, 0.5:1 and 0:1, in TE buffer (10 mM Tris, 1 mM 
EDTA, pH 7.5), with a fixed final DNA concentration (20 µg/mL). Uncomplexed DPSSC, 
equivalent to 10:1 and 20:1 dendrimer: DNA weight ratios, were also run as controls to rule out 
any interference from DPSSC. Each sample solution (10 µL) was mixed with loading buffer (2 
µL, Bioline, UK), before being loaded on a 1X Tris-Borate-EDTA (TBE) (89 mM Tris base, 89 
mM boric acid, 2 mM Na2-EDTA, pH 8.3) buffered 0.8% (w/v) agarose gel containing ethidium 
bromide (0.4 µg/mL), with 1x TBE as a running buffer. The HyperLadder 1Kb (Bioline, UK) 
was used as a DNA size marker and the gel was run at 50 V for 1 h before being photographed 
under UV light. 
 
2.16. Size and zeta potential measurement of DPSSC –DNA complexes 
Hydrodynamic diameter and zeta potential of DPSSC-DNA complexes at various dendrimer: 
DNA weight ratios (0.5:1, 1:1, 2:1, 5:1, 10:1 and 20:1) was assessed using Malvern NanoZS 
instrument (Malvern Instruments, Malvern, UK) immediately after mixing a fixed amount of 
DNA (50 µg) to dendrimer solutions in PBS (pH 7.4).  
 
2.17. Morphology of DPSSC –DNA complexes 
The morphology of DPSSC–DNA complexes was observed using JEOL JEM-1200EX 
transmission electron microscope (Jeol, Tokyo, Japan) operating at an accelerating voltage of 80 
kV. A fixed amount of DNA (50 µg) was mixed with DPSSC in PBS (pH 7.4) at dendrimer: 
DNA weight ratios of 5:1 and 10:1, before being drop-cast (3 µL of each complex) on a carbon-
coated copper grid (400 mesh size), then kept in a desiccator overnight for drying before 
imaging. 
 
2.18. Cell culture  
Minimum Essential Medium (MEM), supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) 
L-glutamine and 0.5% (v/v) penicillin–streptomycin was used as medium to culture monolayers 
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of human prostate adenocarcinoma PC3-Luc cells at 37 °C in a 5% carbon dioxide humid 
atmosphere. 
 
2.19. Cell viability measurement 
PC3-Luc cells were seeded at a density of 5000 cells per well in 96-well plates in MEM medium 
and left to grow at 37 °C for 24 h in a 5% carbon dioxide, humid atmosphere to assess the cell 
viability using a standard MTT assay. After 24 h, the medium was removed and cells were then 
treated with various concentrations of DPSSC, CPT and DAB (in CPT equivalent 
concentrations). After treatment for 24, 48 and 72 h, 50 µL of MTT solution (5 mg/mL in PBS 
pH 7.4) was added in each well and the cells were incubated for 4 h at 37 °C. Following the 
removal of the medium, the formazan dye produced during the reduction of MTT by the living 
cells, was solubilized by adding 200 µL DMSO in each well. The plates were kept at 37 °C in 
incubator for 30 min to solubilize formazan dye completely before being measured at 540 nm 
with a Multiskan Ascent® plate reader (Thermo Scientific, Waltham, MA). 
 
2.20. Cellular uptake of dendriplex  
2.20. 1. Qualitative analysis  
The cellular uptake of DPSSC complexed to DNA was qualitatively assessed using confocal 
microscopy. Plasmid DNA was labeled with the fluorescent probe Cy5 using a Label IT® Cy5 
Nucleic Acid Labeling kit, as described by the manufacturer. PC3-Luc cells were seeded on 
coverslips in 6-well plates at a concentration of 2x105 cells per well in 3 mL MEM media, and 
left to grow at 37 °C. After 24 h, the medium was removed and the cells were then treated with 
Cy5-labelled DNA (2.5 µg/well) complexed to DPSSC, at various dendrimer: DNA weight ratios 
(5:1, 10:1 and 20:1). Cells were treated with DAB dendriplex (dendrimer: DNA weight ratio of 
5:1) and DNA solution as positive and negative controls, along with untreated cells. After 2 
hours of incubation at 37 °C, the cells were then washed twice with 2 mL phosphate buffered 
saline (pH 7.4) before being fixed with 2 mL methanol for 10 min at 20 oC. Methanol was then 
removed and the nuclei of the cells were then stained with Vectashield® mounting medium 
containing propidium iodide (PI). Treated cells were examined using a Leica TCS SP5 confocal 
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microscope (Wetzlar, Germany). Nuclear staining agent PI was excited with the 543 nm laser 
line (emission bandwidth: 597-647 nm), Cy5 (which labeled the DNA) was excited with the 633 
nm laser line (emission bandwidth: 663-709 nm). CPT was excited with the 405nm UV laser line 
(emission bandwidth: 400-480 nm). 
 
2.20.2. Quantitative analysis  
Cellular uptake of DPSSC complexed to DNA was quantified using flow cytometry. Plasmid 
DNA was labeled with the fluorescent probe FITC using a Label IT® FITC Nucleic Acid 
Labeling kit, as described by the manufacturer. PC3-Luc cells were seeded at a density of 2x105 
cells per well in 6-well plates, and left to grow at 37 °C. After 24 h, the medium was removed 
and the cells were treated with fluorescein-labeled DNA (2.5 µg DNA/well) complexed with 
DPSSC at dendrimer: DNA weight ratios 5:1, 10:1 and 20:1. Cells were treated with DAB 
dendriplex (dendrimer: DNA weight ratio of 5:1) and DNA solution as positive and negative 
controls, along with untreated cells. After 2 h incubation with the treatments, the medium was 
removed and washed with 2 mL PBS (pH 7.4) three times and finally single cell suspensions 
were prepared once the cells have detached after addition of 250 µL trypsin followed by 500 µL 
medium per well.  FACSCanto® flow cytometer (BD, Franklin Lakes, NJ) was used to quantify 
the cellular uptake analyzing mean fluorescence intensity by FACSDiva® software (BD, Franklin 
Lakes, NJ), counting ten thousand cells (gated events) for each sample.  
 
2.21. Gene transfection  
Gene transfection of DPSSC complexed to plasmid DNA encoding Green Fluorescent Protein 
(GFP) was carried out by flow cytometry on PC3-Luc cell line. The cells were seeded at a 
density of 1x105 cells per well in 6-well plates and let to grow at 37 °C. After 24 h, the medium 
was removed and the cells were treated with DNA (10 µg DNA/well) complexed with DPSSC at 
various dendrimer: DNA weight ratios (5:1, 10:1 and 20:1). Cells were also treated with DAB 
dendriplex (dendrimer: DNA weight ratio of 5:1) and DNA solution as positive and negative 
controls, along with untreated cells. After 24 h incubation with the treatments, the medium was 
removed, but the cells were not washed with PBS. Single cell suspensions were prepared once 
the cells have detached after addition of 250 µL trypsin followed by 500 µL medium per well.  
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FACSCanto® flow cytometer (BD, Franklin Lakes, NJ) was used to quantify the cellular uptake 
analyzing mean fluorescence intensity by FACSDiva® software (BD, Franklin Lakes, NJ), 
counting ten thousand cells (gated events) for each sample. 
 
2.22. Statistical analysis 
Results were expressed as means ± standard error of the mean. One-way analysis of variance and 
Tukey multiple comparison post-test (Minitab® software, State College, PE) was used to assess 
the statistical significance. Differences were considered statistically significant for P values 








3. Results and discussion 
3.1. Synthesis and characterization of the disulfide-linked camptothecin-bearing PEGylated 
dendrimer 
Disulfide-linked camptothecin bearing PEGylated dendrimers DAB-PEG-SS-CPT (DPSSC) was 






Figure 1. General synthetic scheme for DAB-PEG-SS-CPT or DPSSC, where m=45. 
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The synthesis of DPSSC was confirmed by FTIR, 1H-NMR, and MALDI-TOF MS. Infrared 
(ATR) spectrum of DPSSC showed the presence of a new peak at 1647 cm-1 (corresponding to 
an amide bond) and the absence of a peak at 1719-1740 cm-1 (corresponding to the succinimidyl 
carboxymethyl ester group of the OPSS-PEG-SCM), in comparison to starting materials (Figure 
S2), thus indicating the successful conjugation of PEG to DAB through an amide bond.  
The conjugation of CPT and PEG to DAB was confirmed by 1H-NMR, as follows: 1H-NMR 
(600 MHz, CDCl3): δ2.38-2.47 ppm, DAB (NCH2-CH2-CH2-N) (a); δ3.84-3.91 ppm, PEG (NH-
CO-CH2-OCH2CH2) (b); δ5.23-5.25 ppm, CPT (CH-CH-N-CO) (c); δ5.67-5.70 ppm, CPT (CH-
CH-O) (d) (Figure S3).  
The purity of DPSSC, free from any thiolated CPT, was demonstrated by HPLC (Figure S4). The 
average molecular weight of DPSSC (m/z = 4480 Da) was determined by MALDI- TOF mass 
spectrometry (Figure S5), indicating that the ratio of conjugated PEG as well as CPT per 
dendrimer was nearly 1. CPT loading in DPSSC was found to be 7.75 wt % based on MALDI-
TOF mass spectrometry (Section S1). The conjugation of CPT to the dendrimer did not 
inactivate the drug: the fluorescence spectrum of DPSSC in DMSO showed an emission 
maximum in the 430 nm region, consistent with the presence of CPT having a closed lactone 










Figure 2. (A) Fluorescence emission spectra (λexc =365nm) of DPSSC and CPT in DMSO. (B) 
Relative fluorescence intensity (I/Io) of Nile Red versus DPSSC concentrations. (C)  
Fluorescence spectra (λexc =365nm) of DPSSC solutions (pH 7.4). (D) Hydrodynamic size of 
DPSSC solutions (pH 7.4) at 37 oC with time (n=3). 
 
 
3.2. Evaluation of the self-assembly formation of dendrimer 
Self-assembly of amphiphilic DPSSC dendrimers in phosphate buffer (pH 7.4) was studied by 
steady-state fluorescence technique using Nile Red (NR) as the probe molecule. NR, a highly 
hydrophobic fluorescent probe, is weakly fluorescent in water, but it shows fluorescence 
intensity when it is being solubilized in a nonpolar medium or within the hydrophobic region of 
any self-assembled aggregate.33 Self-assembly formation of DPSSC was confirmed by a gradual 
rise of fluorescence intensity of Nile Red with increasing dendrimer concentrations in PBS (pH 
7.4) (Figures S6). The critical aggregation concentration (CAC) (~200 µg/mL) was calculated 
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from the inflection point of the plot of relative fluorescence intensities of NR at various 
dendrimer concentrations (Figure 2B). DPSSC dendrimer was still able to undergo self-
assembly, even with its low hydrophobicity content at pH 7.4.  The fluorescence emission 
intensity of DPSSC above the CAC did not increase linearly with increasing DPSSC 
concentrations, but instead exhibited a sharp decrease from 1 mg/mL (Figure 2C). This decrease 
in emission intensity was attributed to the static quenching caused by the closer proximity of the 
CPT molecules with increasing DPSSC concentrations, further confirming the self-assembly of 
DPSSC.20, 26  
 
3.3. Hydrodynamic size and zeta potential of dendrimer self-assembled nanostructures 
The hydrodynamic size of DPSSC nanostructures (0.5, 1 and 2 mg/mL) incubated at 37 oC 
sharply decreased with time and became steady after 12 h at around 250-300 nm (for 0.5 mg/mL) 
and 150-200 nm (for 1 and 2 mg/mL) (Figure 2D). This decrease might be explained by the 
formation of more stable and compact nanostructures at higher concentrations, resulting from 
increased hydrophobic interactions among CPT molecules of DPSSC at higher concentrations 
supporting the fluorescence quenching results (Figure 2C). In contrary, at comparatively lower 
concentration (0.2 mg/mL), near CAC, DPSSC did not show any decrease in hydrodynamic size 
with time, indicating a less compact nature of the aggregates. In addition, the size of DPSSC was 
even smaller (~100 nm) in presence of complete medium containing 10% FBS. It was stable over 
time (ranging from 109 ± 4 nm to 105 ± 1 nm following 1h and 24h incubation with the medium) 
at 37 oC (Figure S7). The size of DPSSC nanostructures in presence or absence of FBS was 
below the cut-off size for extravasation, which is 400 nm for most tumors.38  
 DPSSC nanostructures (0.5-2 mg/mL) were bearing a positive zeta potential comprised between 
3 and 5 mV for up to 7 days (Table 1). This would increase their electrostatic interactions with 
the negatively charged cellular membranes, which is favorable to an enhanced cellular uptake of 






Table 1. Zeta potential of self-assembled DPSSC nanostructures in phosphate buffer (pH 7.4) 









3.4. Formation of dendrimer-based vesicles 
TEM images of DPSSC revealed that DPSSC dendrimer assembled into unilamellar, 
spherical-shaped vesicles (dendrimersomes) with a size lower than 100 nm (Figure 3). TEM 
images also showed that DPSSC started forming vesicles at comparatively lower concentrations 
close to the CAC value, but the vesicles became more regular-shaped with increasing 
concentrations of dendrimer, supporting the formation of more compact aggregates at higher 
concentrations. The size of dendrimersomes obtained from the TEM images was found to be 
smaller than that observed with DLS, as TEM imaging technique involves drying of the samples 










    
DPSSC solutions 
(mg/mL) 
Zeta Potential (mV)  
After 6 h After 7 days 
0.2 0.95 ± 0.22 -0.13 ±  0.23 
0.5 3.32 ± 0.18  3.59 ± 0.59 
1 4.21 ± 0.65 4.97 ± 0.49  
2 4.38 ± 0.39 4.85 ± 0.81  









Figure 3. TEM images of DPSSC solution (pH 7.4) at various concentrations:  0.2 mg/mL(A), 
1.0 mg/mL(B) and 2.0 mg/mL(C) (scale bar: 100 nm).   
 
 
3.5. Micropolarity of dendrimer-based vesicles 
The steady-state fluorescence spectrum of coumarin-153 (C153) in presence of DPSSC showed a 
steady increase of fluorescence intensity of emission maximum (Figure 4A), suggesting an 
increasing hydrophobicity of the microenvironment of dendrimersomes. The appearance of a 
shoulder band at ∼490nm was observed from 0.5 mg/mL dendrimer solution. The intensity of 
this shoulder band gradually increased with DPSSC concentrations and a characteristic blue shift 
of emission maximum of C153 was observed for 2 mg/mL DPSSC in comparison to its low 
concentration counterpart. The appearance of the shoulder band indicated a distribution of C153 
at multiple locations in vesicular assemblies, similar to other steroidal skeleton-based vesicular 
structure.40 The blue shift of the emission maximum (λmax = 494 nm) of C153 solubilized within 
DPSSC (2 mg/mL) predicted the micropolarity (π*-value=0.278) of the hydrophobic 
microenvironment of bilayer, which is similar to the polarity of hexafluorobenzene (0.27).41 This 








Figure 4. (A) Fluorescence spectra of C153 (λexc: 420 nm, λem: 430-700 nm) in presence and 





3.6. CPT Packing within dendrimer-based vesicles 
To investigate the CPT packing within the vesicles, circular dichroism (CD) spectra of DPSSC 
(2 mg/mL) in phosphate buffer (pH 7.4) and DMSO was recorded. DPSSC displayed distinctive 
CD signals in the CPT absorption regions between 330 and 400 nm in buffer, whereas no CD 
signal was obtained for DPSSC dissolved in DMSO, where the DPSSC dendrimers are expected 
to exist in a monomeric form (Figure 4B).25 As CD measures absorption differences between left 
and right circularly polarized light, these results suggest a chiral packing of the CPT moieties in 
the vesicles with negative chirality and left-handed helical arrangement. 
 
3.7. Evaluation of redox sensitivity of dendrimer-based vesicles 
In presence of glutathione, the vesicle bilayers are expected to disassemble, with a concomitant 
release of CPT. The redox-sensitive nature of DPPSC was investigated at pH 7.4, as it has 
previously been reported that thiol−disulfide exchange reactions could occur under mild or 
neutral conditions with quantitative or near-quantitative yields, unlike that observed in acidic 
conditions.42 CPT release from DPSSC vesicles was found to be minimal (about 10 to 15%) in 
non-redox condition, as well as in presence of 10 µM GSH (equivalent to the extracellular 
concentration in normal cells) (Figure 5). This might be explained by the absence of disruption 
of dendrimersomes at this GSH concentration, which is supported by the stability of vesicle size 
(around 100 nm) and zeta potential (around 5 mV) at these experimental conditions (Figure S8 
and Table S1). In presence of 10 mM GSH (equivalent to the intracellular concentration in 
normal cells), the CPT release increased to about 30-35% within 7 days (Figure 5), due to the 
breakage of disulphide bonds, resulting in the formation of less compact, larger sized vesicles 
with lower zeta potential (Figure S8 and Table S1). The CPT release sharply increased with time 
to about 70%, in presence of 50 mM glutathione (equivalent to the intracellular environment of 
tumor tissue), responsible for a further disintegration of dendrimersomes and generation of 
smaller sized, nearly disintegrated aggregates (~10 nm) bearing a more positive zeta potential 
(~23 mV). The sustained, high release of CPT in tumor-relevant reductive conditions therefore 





Figure 5. Cumulative CPT release (%) from DPSSC solution (1 mg/mL, phosphate buffer, pH 
7.4) with time in presence and absence of GSH at 37 °C (n=3). 
 
 
3.8. Characterization of dendriplex formation 
3.8.1. Evaluation of DNA condensation. The protonated primary amines of the CPT-bearing 
PEGylated dendrimer can efficiently bind to negatively charged phosphodiester groups of DNA 
through electrostatic interactions leading to the formation of dendrimer: DNA complexes 
(dendriplexes). PicoGreen®, an intercalating fluorochrome, selectively binds double-stranded 
DNA followed by a significantly increased fluorescence intensity. In contrary, successful 
dendriplex formation between the negatively charged dsDNA and positively charged dendrimer 
through electrostatic interactions can knockout PicoGreen® from the DNA groove, resulting in a 
decrease in the fluorescence intensity of the PicoGreen®. Figure 6A showed a gradual reduction 
of fluorescence intensity of PicoGreen® with increasing DPSSC: DNA ratio, confirming DNA 
condensing ability of DPSSC vesicles. PicoGreen® assay also demonstrated that DPSSC 
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dendrimersomes condensed more than 85% of the DNA at dendrimer: DNA weight ratios of 5:1 
and higher (Figure 6B). DNA condensation occurred instantly and was found to be stable for at 
least 24 h (Figures 6B). Furthermore, the fluorescence emission of DPSSC or conjugated CPT in 
pro-drug dendrimer, in presence and absence of DNA, did not show any change in spectral 
pattern confirming no interference from CPT on DNA condensation (Figure S9). 
These results from PicoGreen® assay were also confirmed by a gel retardation assay. Figure 6C 
showed also a complete DNA condensing ability of DPSSC at dendrimer: DNA weight ratios of 
5:1 and higher. The absence of bands from two uncomplexed DPSSC, at two equivalent 
concentrations (10:1 and 20:1) and same exposure level, also ruled out any possibility of 





Figure 6. (A) Fluorescence emission spectra (λexc: 480 nm) of PicoGreen (PG) in presence of 
dendriplexes at DPSSC: DNA weight ratios of 0.5:1, 1:1, 2:1, 5:1, 10:1 and 20:1 (control: PG in 
presence and absence of DNA). The amount of DNA was fixed at 10µg for each complex. (B) 
DNA condensation ability of DPSSC-based dendriplexes using PicoGreen® assay with time at 
various dendrimer: DNA weight ratios (n=4); (C) Gel retardation assay of DPSSC-DNA 
complexes at various dendrimer: DNA weight ratios (0.5:1, 1:1, 2:1, 5:1, 10:1,20:1) (controls: 
uncomplexed DPSSC at two equivalent concentrations (10:1 and 20:1), DNA only). The amount 
of DNA was fixed at 20 µg for each complex. 
29 
 
3.8.2. Size, charge and shape of dendriplex. DPSSC dendriplexes showed a decrease in size 
with increasing dendrimer: DNA ratios, to reach an average size lower than 150 nm at 
dendrimer: DNA ratios of 5:1 and higher, with a low polydispersity index (0.15 to 0.3) (Figure 
7A). The reduction in size of dendriplexes, at dendrimer: DNA ratios of 5:1 and higher, might be 
attributed to the complete condensing ability of DPSSC from that weight ratio as evidenced by 
PicoGreen® and gel retardation assay. Their smaller size may facilitate their extravasation to 
cancer cells more easily than for larger, unmodified DAB dendriplexes (average size of 196 nm, 
polydispersity index: 0.683).10 These complexes displayed an increase in zeta potential with 
increasing dendrimer: DNA ratios, to reach a slightly positive surface charge (0.5 mV) at 
dendrimer: DNA ratios higher than 5:1 (Figure 7A). DPSSC has retained its ability to form 
vesicles of sizes less than 100 nm even after complexation with DNA, as demonstrated by TEM 





Figure 7. (A) Size and zeta potential of DPSSC-based dendriplexes (pH 7.4) at various 
dendrimer: DNA weight ratios at 37 oC (n=3); (B) TEM image of DPSSC-based dendriplex at 





3.9. In vitro analysis 
3.9.1. Evaluation of cell viability. The cell viability following treatment with DPSSC 
dendrimersomes was evaluated by a MTT assay on PC-3M-Luc prostate adenocarcinoma cell 
line. Treatment of the cells with DPSSC dendrimersomes resulted in a higher cell viability than 
for DAB or free CPT after 24, 48 and 72 h (Table 2, Figure S10).  This might be explained by 
the slow release of CPT from the stable, self-aggregated pro-drug dendrimer and the PEGylation 




Table 2. Viability of PC3-Luc cells, expressed as IC50 values, following treatment with DPSSC 
dendrimersomes for 24, 48 and 72 h (controls: DAB and CPT) (n=15). 
        
Time (h) 
IC50 (µg/mL) (mean ± S.E.M.) 
DPSSC DAB Free CPT 
24 11.46 ± 0.97  7.06 ± 0.63 0.08 ± 0.03  
48 9.84 ± 0.48  6.27 ± 0.86  0.15 ± 0.05  
72 8.61 ± 0.98 5.49 ± 0.58  0.17 ± 0.07  
 
3.9.2. Cellular uptake of dendriplexes.  
3.9.2.1. Qualitative analysis. The ability of DPSSC dendrimersomes complexed with 
fluorescently labelled Cy5-DNA to be taken up by PC-3M-Luc cancer cells following 2 h 
incubation was assessed by confocal microscopy. Confocal microscopy (Figure 8) confirmed the 
cellular uptake of complexed Cy5-DNA (green fluorescence) and conjugated CPT (blue 
fluorescence) carried by the dendrimersomes, which appeared to be higher than that observed 
with DAB dendriplex (dendrimer: DNA ratio: 5:1). CPT uptake appeared to be highest after 
treatment with the dendrimersomes at a ratio of 20:1 among all three tested ratios, unlike DNA 
uptake which was similar for the 3 ratios. Both CPT and DNA were found to be co-localized in 







Figure 8. Confocal microscopy images of the cellular uptake of Cy5-labelled DNA (2.5 




3.9.2.2. Quantitative analysis. This DNA cellular uptake was quantitatively confirmed by flow 
cytometry (Figures 9A and S11). The highest cellular fluorescence of fluorescein-labelled DNA 
was observed at a dendrimer: DNA ratio of 5:1 (mean fluorescence intensity (MFI) of 4123 ± 45 
arbitrary units (a.u.)), which was respectively 1.6-fold and 16.3-fold higher than that observed 
after treatment with DAB dendriplex (2524 ± 139 a.u.) and DNA solution (252 ± 2 a.u.). High 





Figure 9. (A) Quantification of the cellular uptake of fluorescein-labelled DNA (2.5 μg/well) 
complexed with DPSSC, by PC3-Luc cells (controls: DAB-DNA, DNA solution) (n=3) (*: P 
<0.05 compared with DAB-DNA). (B) Transfection efficacy of DPSSC complexed with DNA 
encoding GFP (10 µg/well) on PC3-Luc cells (controls: DAB-DNA (5:1 ratio), DNA solution) 
(*: P <0.05 compared with DAB-DNA). 
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3.9.3. Evaluation of gene expression of DPSSC dendrimersomes complexed with DNA. 
DPSSC dendrimersomes complexed with DNA were able to increase the cellular uptake and 
transfection level of DNA (Figure 9B). The dendrimersomes complexed with DNA encoding 
green fluorescent protein (GFP) at dendrimer: DNA ratios of 20:1, 10:1 and 5:1 led to higher 
gene transfection than with DAB dendriplex by respectively 2.2-fold, 2.4-fold and 1.3-fold 
following 24 h incubation. The percentage of GFP-positive cells followed a similar pattern, with 
17.4 ± 0.4%, 14.6 ± 0.7 % and 9.6 ± 0.4 % of cells being GFP-positive following incubation with 
complexes at ratios of 20:1, 10:1 and 5:1. By contrast, only 1.3 ± 0.1% of cells were GFP-
positive following treatment with DAB dendriplex.  
To the best of our knowledge, this is the first report on CPT-bearing PEGylated 
polypropylenimine dendrimer forming spontaneous, redox-sensitive, stable cationic vesicles 
(dendrimersomes), with an additional capability to carry DNA leading to enhanced gene 
expression in prostate cancer cells. Other CPT-modified various polymers, including dendrimers, 
have previously been reported but only as drug delivery carriers.43-45 Earlier report on redox-
responsive pro-drug delivery system from CPT-bearing linear dendritic molecules showed a 
comparatively burst release, but in presence of intracellular redox condition (10 mM DTT) of 
normal cells, unfavorable due to its non-tumor-specific nature.46 Self-assembled nanostructures 
were also reported from amphiphilic polypropylenimine dendrimers, but without exhibiting any 
redox-sensitive release of drug and gene transfection.47 Prior reports on redox-responsive 
PAMAM to deliver either DNA or hydrophobic drugs were unable to show the formation of any 
vesicles and possibility of co-delivery of drugs and nucleic acids.48-49  This current study 
demonstrated that the pro-drug dendrimer DPSSC can be used as a single carrier for dual 
delivery of drug and DNA to cancer cells, which makes it a much more promising carrier than a 
mixture of delivery systems each carrying a single therapeutic agent.50 
 
4. Conclusion 
In this proof-of-concept study, a disulfide-linked CPT-bearing PEGylated dendrimer has been 
successfully synthesized through in situ two-step reactions. To our knowledge, this is the first 
report of CPT-conjugated PEGylated dendrimer able to spontaneously self-assemble into cationic 
vesicles (~3-5 mV) (dendrimersomes) that were stable over 7 days. The bilayer of these 
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dendrimersomes were made of hydrophobic CPT molecules with negative chirality and left-
handed helical arrangement of the drug. The dendrimersomes were also able to entrap an 
additional guest inside their nanostructure, indicating their capability to carry another 
encapsulated chemotherapeutic drug in addition to CPT. They were able to release about 70% of 
the conjugated camptothecin in presence of 50 mM glutathione (equivalent to the intracellular 
environment of tumor tissue), in a sustained manner and with a gradual breakage of their 
nanostructures.  Furthermore, CPT-bearing PEGylated dendrimer was able to form positively 
charged (~0.5-2 mV), smaller-sized (less than 150 nm) and stable complexes with plasmid DNA, 
condensing more than 85% of the DNA at dendrimer: DNA weight ratios of 5:1 and higher. 
These dendriplexes led to an enhanced cellular uptake of DNA (by up to 1.6-fold) and increased 
gene transfection (by up to 2.4-fold) in prostate cancer cells in comparison with that of the highly 
efficacious unmodified DAB dendrimer.  We believe this strategy could be extended to the 
synthesis of other supramolecular nanostructures for dual delivery of anti-cancer drugs and 
nucleic acids, with the aim of potentially getting synergistic therapeutic effects on cancer cells. 
This disulfide-linked CPT-bearing PEGylated dendrimer formulation has the potential to be 
further tailored to respond to a variety of delivery hurdles encountered in cancer treatment, 
ultimately optimizing the therapeutic efficacy of its cargo. This novel dendrimersome therefore 
holds promising prospects for the redox-triggered combination delivery of anti-cancer drugs and 
nucleic acids for cancer therapy.  
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Figure S1. 1H-NMR spectrum of thiolated camptothecin CPT-SH (in DMSO-d6, 500 MHz). 
 
1H NMR (500 MHz, DMSO-d6, δ ppm): 8.71 (s, 1H), 8.16 (m, 2H), 7.87-7.90 (m, 1H), 7.72-7.75 (m, 1H), 
7.19 (s, 1H), 5.52 (s, 2H), 5.32 (s, 2H), 3.20 (m, 1H), 2.87-2.90 (m, 2H), 2.70-2.74 (m, 2H), 2.17-2.19 (m, 







































Figure S2. FTIR spectrum of CPT-bearing PEGylated DAB dendrimer (DPSSC) (A), DAB (B), 










































































Figure S5. MALDI-TOF MS spectra of DPSSC (A), DAB (B) and OPSS-PEG-SCM (C) 
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S1. CPT loading calculation 
The CPT loading in DPSSC was calculated as the weight of conjugated CPT expressed as a percentage of 
the total average molecular weight: 
CPT loading (%) = {(n x MWconjugated CPT)/[M]+}x 100 
Where n is the number of CPT conjugated to modified dendrimer, MWconjugated CPT is the molecular weight 
of conjugated CPT (347.35 g/mol) and [M]+ is the average molecular weight of the modified dendrimer 
(4480 g/mol), as obtained from MALDI-TOF mass spectrometry analysis.  





















Figure S6. Fluorescence spectra of Nile Red in presence of DPSSC at various concentrations in phosphate 
buffer (pH 7.4) 
 
 


















































Figure S7. Size of DPSSC (2 mg/mL) incubated in presence of complete medium containing 







































Figure S8. Size distribution of DPSSC (1 mg/mL, phosphate buffer (pH 7.4) in presence of various GSH 
concentrations: 0 (A), 10µM (B), 10mM (C) and 50mM (D) 
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Table S1. Zeta potential of DPSSC (1 mg/mL, phosphate buffer of pH 7.4) incubated in presence of 














      
DPSSC solutions 
(1 mg/mL) 
Zeta Potential (mV)  
After 6 h After 7 days 
No GSH 4.21 ± 0.65  4.97 ± 0.49 
10 µM GSH NA 4.09 ± 0.64  
10 mM GSH NA 0.46 ± 0.06  
50 mM GSH NA 23.1 ± 2.55  




















Figure S9. Fluorescence emission spectra (λexc: 365 nm) of DPSSC complexed with DNA at DPSSC: DNA 
weight ratio of 20:1, in presence of PicoGreen (PG) (control: DPSSC only (200 µg/mL)). The amount of 
DNA was fixed at 10µg for each complex. 


















































Figure S10. Cell viability of DPSSC, DAB and free CPT on PC3-Luc human prostate cancer cells at 
various concentrations after 24 (A) 48 (B) and 72 h (C) of incubation. The data points are mean ± SD. (n 
= 5).  
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Figure S11. Flow cytometry histograms of PC3-Luc cells following 2 hours incubation with DPSSC-DNA 
complexes (dendrimer: DNA weight ratios: 20:1 (A), 10:1 (B), 5:1 (C) and 10:1 (D)) (controls: DAB 
dendriplex (dendrimer: DNA weight ratio 5:1 (E)) and DNA solution (F)) 
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